Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 5

Explainer

Semaglutide tied to lower seizure risk

A target trial emulation using the All of Us database found semaglutide users had roughly half the seizure risk of adults on other glucose-lowering drugs.

20 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide may protect joints via muscle

A 2026 mouse study reports that semaglutide restores muscle mitochondrial function, raises glutamine, and reduces cartilage inflammation.

20 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide CV edge over tirzepatide

A 47-trial meta-analysis finds semaglutide cuts MACE by 29% and CV death by 19%. Tirzepatide trends protective but lacks the trial base to confirm it.

20 Jun 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

Semaglutide vs SGLT2 inhibitors in MASLD

A propensity-matched TriNetX study compares semaglutide against SGLT2 inhibitors in patients with fatty liver disease and type-2 diabetes.

20 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide vs GLP-1s in spinal fusion

A 2026 retrospective study found tirzepatide users had fewer complications and revisions after spinal fusion than single-receptor GLP-1 agonist users.

20 Jun 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

Weight-loss drugs and fertility: the data

A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.

20 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

BPC-157 side effects: what the data shows

BPC-157 has no approved label and no completed human safety trial. Here is what preclinical toxicology actually shows.

19 Jun 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

BPC-157 and anxiety: what the evidence says

Rodent studies suggest BPC-157 has anxiolytic effects. Human self-reports are mixed. No controlled human trial has measured anxiety as an outcome.

19 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

BPC-157 oral vs injectable for gut health

No human trial has compared oral BPC-157 tablets to reconstituted injectable for gut health. Here is what rodent data and the supply chain show.

19 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

BPC-157 personal reviews: what they show

Personal peptide reviews name doses and outcomes but lack controls and verified purity. Here is how to read them against actual BPC-157 data.

19 Jun 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

Is BPC-157 prohibited in sport? WADA rules

BPC-157 is banned under S0 of the WADA Prohibited List. Here is how the rule works, what USADA enforces, and what athletes need to know.

19 Jun 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How BPC-157 works: a plain-English guide

BPC-157 appears to promote tissue repair in rodents through angiogenesis and nitric-oxide signalling. Here is what the preclinical data shows.

18 Jun 2026 · PeptideMethods Editorial Team · 4 min read